• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

AJMC in the Press, October 14, 2016


Coverage of our peer-reviewed research in the healthcare and mainstream press.

In the October 3, 2016, edition of Medical Economics, Mark L. Fuerst discussed the commentary in a special issue of The American Journal of Managed Care on novel direct-acting antivirals (DAAs). Darius Lakdawalla, PhD, of the University of Southern California’s Schaeffer Center for Health Policy and Economics, wrote that cost-sharing plans that impose large out-of-pocket costs on DAAs for patients with hepatitis C virus (HCV) are “suboptimal solutions,” because they impose financial burdens on patients “at a time when they are least able to cope with them.” For the rest of the special issue on policy questions surrounding HCV treatment and cost-sharing, click here.

Related Videos
Dr Jessica Robinson-Papp
Dr. Jessica Robinson-Papp
Dr. Robinson-Papp
Related Content
© 2023 MJH Life Sciences
All rights reserved.